The Epstein-Barr Virus (EBV) Deubiquitinating Enzyme BPLF1 Reduces EBV Ribonucleotide Reductase Activity by Whitehurst, C. B. et al.
JOURNAL OF VIROLOGY, May 2009, p. 4345–4353 Vol. 83, No. 9
0022-538X/09/$08.000 doi:10.1128/JVI.02195-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
The Epstein-Barr Virus (EBV) Deubiquitinating Enzyme BPLF1
Reduces EBV Ribonucleotide Reductase Activity
Christopher B. Whitehurst,1 Shunbin Ning,1 Gretchen L. Bentz,1 Florent Dufour,4 Edward Gershburg,5
Julia Shackelford,3 Yves Langelier,4 and Joseph S. Pagano1,2*
Departments of Medicine,1 Microbiology and Immunology,2 and Cell and Developmental Biology,3
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill,
North Carolina 27599; Centre de Recherche du Centre Hospitalier de l’Université de Montréal and
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A newly discovered virally encoded deubiquitinating enzyme (DUB) is strictly conserved across the Herpes-
viridae. Epstein-Barr virus (EBV) BPLF1 encodes a tegument protein (3,149 amino acids) that exhibits
deubiquitinating (DUB) activity that is lost upon mutation of the active-site cysteine. However, targets for the
herpesviral DUBs have remained elusive. To investigate a predicted interaction between EBV BPLF1 and EBV
ribonucleotide reductase (RR), a functional clone of the first 246 N-terminal amino acids of BPLF1 (BPLF1
1-246) was constructed. Immunoprecipitation verified an interaction between the small subunit of the viral
RR2 and BPLF1 proteins. In addition, the large subunit (RR1) of the RR appeared to be ubiquitinated both
in vivo and in vitro; however, ubiquitinated forms of the small subunit, RR2, were not detected. Ubiquitination
of RR1 requires the expression of both subunits of the RR complex. Furthermore, coexpression of RR1 and
RR2 with BPLF1 1-246 abolishes ubiquitination of RR1. EBV RR1, RR2, and BPLF1 1-246 colocalized to the
cytoplasm in HEK 293T cells. Finally, expression of enzymatically active BPLF1 1-246 decreased RR activity,
whereas a nonfunctional active-site mutant (BPLF1 C61S) had no effect. These results indicate that the EBV
deubiquitinating enzyme interacts with, deubiquitinates, and influences the activity of the EBV RR. This is the
first verified protein target of the EBV deubiquitinating enzyme.
Ubiquitination of proteins plays an indispensable role in
many cellular and viral processes (22). Ubiquitination pro-
ceeds in steps through the activity of three types of proteins:
E1, ubiquitin (Ub)-activating enzymes; E2, Ub-conjugating
proteins; and E3 enzymes, which are Ub ligases (29). Wild-type
Ub is 8 kDa in length and is attached to its substrate via its
C-terminal glycine 76 to lysine residues in the target protein
(32). Ub modification of proteins occurs on lysine residues and
may consist of a single Ub (monoubiquitination) or multiple
Ubs in which a chain is linked together on the same substrate
site (polyubiquitination). Ub has seven potential lysines (K6,
K11, K27, K29, K33, K48, and K63) that can be used to form
polyubiquitin chains (29). Polyubiquitin linkages through K48
or K63 have been well studied. K48-linked Ub chains typically,
but not always, target proteins to the proteasome for degrada-
tion (26, 33). In contrast, K63-linked Ub chains are typically
involved in the signaling, trafficking, and regulatory responses
of their protein substrates (1, 9, 19, 28, 39). More recently
appreciated is that protein ubiquitination can be reversed
through the action of deubiquitinating enzymes (DUBs) (43,
44).
All members of the Herpesviridae family encode a large teg-
ument protein containing deubiquitinating activity located
within their N-terminal regions (34). Members of this unique
class of deubiquitinating enzymes function as cysteine pro-
teases and have a strictly conserved catalytic triad composed of
a cysteine, histidine, and aspartic acid residue. Sequence ho-
mology over the N-terminal region is only about 15% among
members of the Herpesviridae (34). Herpesvirus DUBs do not
share sequence homology or conserved domains with known
eukaryotic DUBs (25). However, the catalytic triad is strictly
conserved and is essential for DUB activity among the herpes-
virus family as well as for cellular DUBs (25, 34). Mutation of
the active-site cysteine or histidine of the human cytomegalo-
virus (CMV) counterpart pUL48 resulted in a complete loss of
DUB activity (25, 42). Such mutations clearly reduced produc-
tion of infectious human CMV and pseudorabies virus in cell
culture (5, 42), demonstrating an important role for virally
encoded DUB activity in the virus life cycle.
BPLF1, a late lytic cycle gene of Epstein-Barr virus (EBV),
produces a full-length transcript of 9.5 kb and an apparent
smaller product approximately 3 kb in length (35). BPLF1 is
3,149 amino acids in length and contains the deubiquitinating
activity within its first 205 amino acids (34). The N-terminal
fragment of the herpes simplex virus (HSV) homolog (UL36),
which encompasses DUB and cleaves polyubiquitin chains,
appears to be specific for K48 linkages; cleavage of K63-Ub
chains was not detected (25). In addition, DUBs from the
alphaherpesviruses and gammaherpesviruses are Ub specific
and show little or no preference for other Ub-like molecules,
such as Nedd8, SUMO, and ISG15 (21, 25).
Recently, an EBV interactome map was constructed with
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the use of rapid yeast two-hybrid screening (6). This map
predicted many possible cellular partners but only one EBV-
interacting partner with BPLF1, BaRF1; BPLF1 was also pre-
dicted to interact with itself. BaRF1 is the small subunit (RR2)
of the EBV ribonucleotide reductase, and it interacted with a
protein fragment containing BPLF1’s first 1,000 amino acids
(6).
EBV RR2 is a lytic cycle gene product 302 amino acids in
length. EBV RR2, which has been studied relatively little, is
similar to cellular RR2 in that it must interact with the large
RR subunit (RR1) to be functionally active (24). Mg2 and
ATP are required for cellular RR activity, but both are dis-
pensable for HSV RR activity (23). Cellular RR activity is
controlled by regulating RR2 stability; RR2 levels are reported
as undetectable during G1 phase, but high levels are detected
during S phase (4), which may be clues to cellular function.
Cellular RR1 protein levels remain constant throughout the
cell cycle (14). In addition, the cellular small subunit, RR2, can
be polyubiquitinated in vitro (8). From a biological standpoint,
functional HSV RR is essential for neurovirulence in mice but
is not needed for virus replication in tissue culture cells (7, 20).
During initial experiments, in which BPLF1 mRNA expres-
sion was suppressed with short hairpin RNA (shRNA), de-
creases in viral particle production resulted, but the effects
could not be attributed directly to DUB activity of BPLF1
since expression of the entire gene was suppressed. In this
report, we verify a physical and functional interaction between
a fragment containing the first 246 amino acids of BPLF1 and
EBV RR, which results in deubiquitination of the EBV RR
large subunit (RR1). Importantly, enzymatically active BPLF1
downregulates viral ribonucleotide reductase activity. The re-
sults suggest that ubiquitination of the large subunit (RR1) of
the EBV RR may upregulate its activity, which is then sup-
pressed by deubiquitination. These data point to the first pro-
tein target identified for a viral DUB and suggest a potential
role of BPLF1 deubiquitinating activity in regulation of EBV
replication.
MATERIALS AND METHODS
Cell lines, growth, and transfection. HEK 293T and 293EBV (green fluo-
rescent protein [GFP]-tagged recombinant B95.8 EBV) cells (11) were cultured
in Dulbecco’s modified Eagle medium (CellGro) supplemented with 10% fetal
bovine serum, penicillin (100 IU/ml), streptomycin (100 g/ml), and amphoter-
icin B (250 ng/ml). Transfections were performed with the use of Effectene
transfection reagent (Qiagen) following the manufacturer’s protocol, and cells
were harvested after 48 h.
Construction of shRNAs against BPLF1. shRNAs (19-mer) predicted to knock
down BPLF1 were designed, constructed, and ligated into pSuperRetro.puro
(OligoEngine) at the BglII and XhoI sites. shRNAs were named according to the
base number they map to in the BPLF1 sequence. 893 was constructed using the
forward primer 5-GATCCCCGGCGAATAATACCGTATAATTCAAGAGA
TTATACGGTATTATTCGCCTTTTTC-3 and the reverse primer 5-TCGAG
AAAAAGGCGAATAATACCGTATAATCTCTTGAATTATACGGTATTA




-3, respectively. The 3650 forward and reverse primers were 5-GATCCCCGT
GAAATCCATCACCTTCTATTCAAGAGATAGAAGGTGATGGATTTCA
TTTTTC-3 and 5-TCGAGAAAAATCAAATCCATCACCTTCTATCTCTT
GAATAGAAGGTGATGGATTTCACGGG-3, respectively. The corresponding
forward and reverse scrambled primers (3650S) were 5-GATCCCCGTATCTT
ATCATACCGCAACTTCAAGAGAGTTGCGGTATGATAAGATATTTTT
C-3 and 5-TCGAGAAAAATATCTTATCATACCGCAACTCTCTTGAAGT
TGCGGTATGATAAGATACGGG-3, respectively. Primers were placed in
annealing buffer (10 mM Tris, pH 7.5, 1 mM EDTA, 100 mM NaCl), brought to
a boil, and allowed to slowly cool to room temperature. Annealed primers were
ligated to BglII and XhoI cut pSuperRetro.puro vector with T4 DNA ligase
(NEB). Correct shRNA sequences were verified after transformation.
Reverse transcriptase PCR (RT-PCR). 293EBV cells were transfected with
shRNA constructs and the BZLF1-expressing construct (to induce the lytic cycle)
(3). After 72 h, the supernatant fluid and cells were harvested. RNA was ex-
tracted from the cell pellet with use of the Zymogen mini RNA isolation II kit
(Orange, CA) and subjected to DNase treatment with the Zymogen DNA-Free
RNA kit. RNA was quantified, and 4 g was used with the high-capacity cDNA
reverse transcription kit (Applied Biosystems, Foster City, CA) to generate
cDNA. Samples were then treated with RNase H. PCR analysis was performed
with primers mapping to either the N-terminal or C-terminal region of BPLF1.
PCR conditions were 95°C for 2 min followed by 25 cycles of 95°C for 30 s, 55°C
for 30 s, and 68°C for 1.5 min with a final extension at 72°C for 10 min. PCR
products were then visualized after separation on 1% agarose gel.
Real-time PCR. Supernatant fluid of shRNA-transfected, lytically induced
293EBV cells was harvested and filtered after 72 h. Genomic DNA was extracted
from 88 l of supernatant fluid with the DNeasy kit (Qiagen) and analyzed by
real-time PCR with the ABI 7900HT real-time PCR system. Primer and probe
sequences were EBVW-1 (5-GCAGCCGCCCAGTCTCT-3), EBVW-2 (5-ACA
GACAGTGCACAGGAGCCT-3), and EBVW-FAM (5-6-carboxyfluorescein-A
AAAGCTGGCGCCCTTGCCTG-6-carboxytetramethylrhodamine-3). PCR con-
ditions were 50°C for 2 min, 95°C for 10 min, 40 cycles at 95°C for 15 s, and 60°C for
1 min. Viral DNA copy numbers were determined by dilution of a quantitated
standard of EBV B95-8 DNA (Advanced Biotechnologies, MD).
Western blotting. After transfection, immunoprecipitation (IP), or in vitro
ubiquitination/deubiquitination, proteins were separated by sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellu-
lose membrane, blocked with 5% milk in Tris-buffered saline–Tween 20, and
incubated with appropriate primary antibody overnight at 4°C. The nitrocellulose
membrane was then washed and probed with either goat or rabbit anti-mouse
antibody (Santa Cruz Biotechnology) at 1:3,000 in 5% milk for 1 h at room
temperature. Bands were visualized with enhanced chemiluminescence reagent
from Pierce (Rockford, IL).
Ub-AMC assay. Ub-AMC (1 M; Biomol) was incubated with 1 M purified
N-terminal BPLF1 or 100 nM Ub C-terminal hydrolase (UCH-L1) (Boston
Biochem) in reaction buffer containing 50 mM Tris, pH 7.5, 2 mM ATP, and 2
mM dithiothreitol (DTT) with and without Ub aldehyde (Ub-al; Santa Cruz
Biotechnology). Reaction mixtures were incubated at 37°C for 10 min, and then
samples in triplicate were excited by exposure to light at a wavelength of 340 nm
and emission was measured at 460 nm.
Construction and purification of EBV clones. The first 246 amino acids of
BPLF1 (BPLF1 N-term) were amplified by PCR analysis using a forward
primer (5-ATGAGTAACGGCGACTGGGGGCAAAGCCAG-3) and a re-
verse primer (5-ATGCGGGGGTCCTCTGTCTC-3). PCR analysis condi-
tions were one cycle of 95°C for 2 min and then 40 cycles of 95°C for 30 s,
55°C for 30 s, and 68°C for 1.5 min, followed by a 10-min extension. Purified
B95-8 EBV DNA was used as template (Advanced Biotechnologies). PCR
products were treated with Taq polymerase (Roche) to add adenosine over-
hangs and ligated into pSC-A with the use of the Strataclone PCR cloning kit
(Stratagene) following the manufacturer’s guidelines. After sequence verifi-
cation, the clone was inserted into His-tagged pET28a (Novagen) at the
EcoRI site and transformed into BL21-Gold DE3 pLysS cells (Stratagene). A
large culture was grown and induced with 1 mM isopropyl--D-thiogalacto-
pyranoside (IPTG), and the cell pellet was resuspended in 40 mM HEPES,
pH 7.9, 1 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride, 500 mM KCl,
10% glycerol, 0.2% NP-40, and 10 mM imidazole. Cells were lysed by soni-
cation, and cleared lysates were incubated with Ni-nitrilotriacetic acid aga-
rose beads (Qiagen). The column was loaded and washed, and purified
protein was eluted with 300 mM imidazole in resuspension buffer.
The BPLF1 N-terminal fragment was cloned into the pFLAG-CMV-2 (Sigma)
vector for expression in 293T cells. To this end, the pSC-A BPLF1 N-terminal
fragment vector served as template for PCR analysis in which primers provided
HindIII and XbaI sites. PCR conditions were the same as those described above
except the annealing temperature was 52°C. The PCR product and pFLAG-
CMV-2 vector were digested with HindIII and XbaI and ligated to yield a
pFLAG CMV-2 BPLF1 N-terminal fragment containing an N-terminal FLAG
tag (BPLF1 1-246).
EBV RR2 was removed from previously cloned pEGFP-C1 (Clonetech) with
BglII and EcoRI and was placed into pCMV-Tag-3B at the BamHI and EcoRI
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sites. This vector contains an N-terminal myc tag. RR1 was cloned into pcDNA3,
and an N-terminal hemagglutinin (HA) tag was added by PCR.
BPLF1 C61S was constructed by utilizing site-directed mutagenesis on BPLF1
1-246. The sequences of the forward primer (C61S FWD) and reverse primer
(C61S REV) were 5-CTTTGCCGGCATCCAGAGCGTCAGCAACTG-3 and
5-CAGTTGCTGACGCTCTGGATGCCGCAAAG-3, respectively. PCR con-
ditions were 95°C for 2 min and then 30 cycles of 95°C for 30 s, 55°C for 30 s, and
68°C for 8 min, followed by a 10-min extension at 72°C.
IP. 293T cells were transfected with FLAG-tagged BPLF1 1-246, myc-tagged
RR2, or both. After 48 h, cells were harvested and placed in lysis buffer (30 mM
NaCl, 1% NP-40, 10 mM Tris, pH 7.5, 1 protease inhibitor cocktail tablet
[Roche], 5 mM DTT, and 1 mM phenylmethylsulfonyl fluoride). Cells were lysed
by freeze-thawing (three times), and samples were precleared with protein A/G
beads (Santa Cruz Biotechnology) at room temperature for 30 min. Supernatant
fluids were collected, 1 g/ml anti-FLAG (Sigma) was added, and samples were
oscillated at 4°C for 1 h. Protein A/G beads (30 l) were added, and samples
were incubated overnight at 4°C. Beads were washed three times in lysis buffer,
placed in SDS sample buffer, and separated by SDS-PAGE. Western blotting was
performed as described above except mouse anti-myc (1:200; Santa Cruz Bio-
technology) served as the secondary antibody.
In vitro ubiquitination and deubiquitination assays. 293EBV cells were
transfected with BZLF1 (to activate lytic infection) along with EBV RR1 and
RR2. After 48 h, cells were harvested and lysed in residual phosphate-buffered
saline (PBS; from PBS rinses during harvesting) by freeze-thawing three times.
Samples were placed in reaction mixture buffer (50 mM Tris, pH 7.5, 2 mM
Mg-ATP [Boston Biochemical], 2 mM DTT, 25 M MG132 [Biomol], 6 l/
sample rabbit reticulocytes [fraction II; Biomol] to provide E1 and E2 enzymes,
2 M Ub-al [Santa Cruz Biotechnology; only for ubiquitination assay], 20 M
His6-tagged Ub [Biomol], and 1 protease inhibitor cocktail [Roche]) and were
incubated at 37°C for the indicated amounts of time. For the deubiquitination
assay only, Ub-al was omitted, and purified EBV BPLF1 1-246 (2 M) was added
after the initial incubation step and then incubated at 37°C for 1 h. Samples were
loaded on SDS-PAGE and transferred to nitrocellulose membrane. Ubiquiti-
nated/deubiquitinated EBV R1 and R2 were detected with anti-EaR (R1) (Santa
Cruz Biotechnology), anti-HA (R1) (Santa Cruz Biotechnology), and anti-myc
(R2) antibodies.
Immunofluorescence assay. HEK 293T cells were grown and transfected on
poly-lysine-treated coverslips. After 24 h, cells were washed with PBS and fixed
with 4% paraformaldehyde. Cells were then permeabilized with 0.5% Triton
X-100 and were blocked with 10% normal donkey serum. Primary antibody
diluted in 1.5% normal donkey serum was added (anti-FLAG [BPLF1 1-247],
anti-HA [EBV RR1], and anti-myc [EBV RR2]), and cells were stored at 4°C
overnight. Cells were washed with PBS and exposed to secondary antibody
(donkey anti-mouse Alexa Fluor 594 and donkey anti-rabbit Alexa Fluor 488;
Invitrogen) at 37°C for 1 h. Cells were stained with 0.1 g/ml 4,6-diamidino-
2-phenylindole (DAPI), mounted, and examined with an Axiovert fluorescent
microscope.
Cell compartmentalization assay. HEK 293T cells were transfected with
BPLF1 1-246, BPLF1 C61S, RR1, and RR2. Cells were harvested after 48 h, and
cell pellets were processed with the Qproteome cell compartment kit (Qiagen).
Fractions were then separated by SDS-PAGE, transferred to nitrocellulose
membranes, and visualized with the appropriate antibodies.
In situ measurements of RR activity. To quantify the RR activity, incorpora-
tion of [3H]cytidine into DNA was performed as described previously (40). HEK
293T cells were transfected with BPLF1 1-246, BPLF1 C61S, RR1, and RR2 in
triplicate. After 24 h, [3H]cytidine (MP Biomedicals) was added to the medium
and samples were incubated for an additional 24 h. Cells were harvested and
treated with RNase, and DNA was purified with the use of the DNeasy kit
(Qiagen) and eluted in a 200-l volume. Incorporation of 3H into DNA was
determined by scintillation counting.
RESULTS
shRNA against BPLF1 decreases mRNA levels and reduces
viral genome production. BPLF1 shRNAs were designed and
transfected into 293EBV cells (11) along with the EBV
transactivator, BZLF1 (Z), to induce viral replication. After
72 h, cells were harvested and total RNA was extracted and
subjected to RT-PCR. Primers for both N-terminal and C-
terminal regions were used to analyze mRNA levels. Figure 1A
shows a representative experiment illustrating that shRNA 893
and 3650 effectively decreased amounts of BPLF1 mRNA. The
scrambled shRNA, 3650S, does exhibit some nonspecific
knockdown of the N-terminal RNA levels.
The effects of BPLF1 shRNAs on virus production were
determined by assaying the number of viral genome copies in
the supernatant fluid of the lytically induced 293EBV cells
with the use of real-time PCR and a TaqMan primer against
the BamH1W segment (17, 18). The results in Fig. 1B dem-
onstrate that expression of 893 and 3650 shRNAs results in
reduced genome copies compared with the scrambled controls.
These data demonstrate that BPLF1 contributes to EBV rep-
lication. However, these effects cannot be directly attributed to
DUB activity alone since BPLF1 serves viral maturation func-
tions that may not require the deubiquitinating activity of the
protein. We therefore set out to investigate the effects of
BPLF1 DUB by examining its interaction with a viral lytic cycle
protein.
EBV BPLF1 1-246 expresses deubiquitinating activity. An
N-terminal clone of BPLF1 containing the first 246 amino
FIG. 1. Knockdown of BPLF1 mRNA levels decreases the EBV
genome copy number. 293EBV cells were induced by transfection
with Z (BZLF1) along with shRNA against BPLF1. 893S and 3650S
denote scrambled forms of 893 and 3650 shRNA constructs. Z serves
as the positive control and pcDNA3 as the negative control. (A) RT-
PCR of RNA from 293EBV cells. Seventy-two hours after transfec-
tion, cells were lysed and total RNA was extracted and subjected to
RT-PCR using primers against the N-terminal or C-terminal portions
of BPLF1. (B) Real-time PCR of 4-l supernatant fluids from shRNA-
transfected 293EBV cells at 72 h. Genomic DNA was extracted from
supernatant fluids and analyzed by real-time PCR with a TaqMan
probe corresponding to the BamHI sequence. The total genome copies
present in the positive control (Z) were set to 100%, and samples are
reported as a percentage of Z.
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acids was constructed, expressed, and purified from Esche-
richia coli, and DUB activity was measured by fluorometry.
BPLF1 1-246 was incubated with a fluorogenic substrate (Ub-
AMC; Biomol) which, when cleaved by a deubiquitinating en-
zyme, releases photons, allowing the fluorescence intensity to
be determined. BPLF1 1-246 caused a high level of cleavage of
Ub-AMC, which was reversed by Ub-al, an irreversible inhib-
itor of DUBs (Fig. 2A). UCH-L1, a cellular DUB with the
same conserved active site as that of BPLF1, was used to
validate the assay and produced similar results.
To determine the type of Ub chain cleaved by the EBV
enzyme, Ub chains linked through Ub-lysine 48 or Ub-lysine
63, in which all lysines except 48 or 63 were mutated, were used
as substrates for BPLF1 1-246 (Fig. 2B). Both K48 and K63-
linked Ub chains were reduced mostly to mono-Ub (Ub1) and
di-Ub (Ub2) forms by the DUB activity with an apparent slight
(but reproducible) preference for K63-linked chains. The re-
sults indicate that both K48- and K63-linked Ub chains are
substrates for EBV DUB in vitro. These observations leave
open the possibilities that BPLF1 1-246 may have roles in
rescuing substrate from degradation in some instances and be
involved in regulating protein function in others.
Finally, an inactive DUB mutant was constructed by site-
directed mutagenesis. The cysteine residue C61 in the catalytic
triad also composed of a histidine and an aspartic acid residue
was converted to serine (BPLF1 C61S) in the BPLF1 1-246
clone. BPLF1 C61S did not exhibit DUB activity in the Ub-
AMC assay when FLAG-tagged versions of BPLF1 1-246 and
BPLF1 C61S were expressed in 293T cells and purified by IP
(Fig. 2C). Loss of DUB activity was observed with BPLF1
C61S compared with that of the wild-type BPLF1 1-246. This
result indicates that the active-site C61 residue is essential for
EBV DUB activity and that BPLF1 C61S serves as a valid
inactive mutant. These data together show that BPLF1 1-246 is
a functional DUB, cleaves Ub chains linked by K48 and K63,
and has a strictly conserved cysteine residue which is required
for its activity.
EBV RR interacts with BPLF1 1-246. Once a functional
clone was obtained, we searched for a target of the EBV DUB
enzyme. Interactome mapping had suggested a possible inter-
action between EBV RR and BPLF1 (6). To determine
whether BPLF1 1-246 could in fact interact with EBV RR,
specifically RR2, FLAG-tagged BPLF1 1-246 and myc-tagged
RR2 were coexpressed in 293T cells. Cells were harvested and
lysed, and IPs were performed with FLAG antibody followed
by immunoblotting with c-myc antibody. Figure 3 demon-
strates the interaction between FLAG-tagged BPLF1 1-246
and myc-tagged RR2 proteins, either physically or through
complex formation. When EBV RR2 or BPLF1 1-246 was
expressed alone, no precipitating protein bands were detected.
Precipitation of RR2 was detected only when both proteins
were coexpressed, suggesting that they may interact physically.
Additionally, it was found that the interaction of RR2 and
BPLF1 was maintained in the presence of RR1.
FIG. 2. BPLF1 1-246 exhibits deubiquitinating activity. (A and C) Functional assay of BPLF1 1-246. BPLF1 1-246 was incubated with Ub-AMC
at 37°C for 10 min. Samples were excited at 340 nm, and emission was measured at 460 nm. Ub-al was added where indicated. UCH-L1 is a known
cellular DUB, and BPLF1 C61S is an enzymatically inactive mutant. (B) Purified BPLF1 was incubated overnight with and without K48 and K63
Ub chains (Ub2 to Ub7), separated by SDS-PAGE, and visualized with Sypro Ruby protein stain. Mono-Ub and di-Ub are labeled Ub1 and Ub2.
The bands located above the labeled mono-Ub and di-Ub bands represent the longer Ub chains (Ub3 to Ub7).
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EBV BPLF1 1-246 localizes intracellularly with EBV RR.
Cell fractionation was used to determine the cellular localiza-
tion of RR1, RR2, and BPLF1 1-246 (Fig. 4A). 293T cells were
transfected with RR1, RR2, and BPLF1 1-246, and cellular
expression of these products was analyzed by cell fractionation.
When RR1 was expressed alone, the product was found in both
the cytoplasmic and nuclear fractions; however, when RR1 is
expressed with RR2 or both RR2 and BPLF1 1-246, the local-
ization is greatly shifted to the cytoplasmic fraction. RR2 is
likely necessary for proper folding and localization of RR1
since both subunits are necessary for RR activity (10, 13, 30).
RR2 is consistently located in the cytoplasm regardless of
whether it is expressed alone or in conjunction with RR1.
BPLF1 1-246 is found in both the nucleus and cytoplasm when
expressed alone or with RR1 or RR2. Upon concurrent ex-
pression, RR1, RR2, and BPLF1 1-246 all colocalize to the
cytoplasm.
Immunofluorescence was utilized to substantiate the cellular
localization of EBV RR1, RR2, and BPLF1 1-246. 293T cells
were transfected with EBV RR1, RR2, and BPLF1 1-246.
After 48 h, cells were washed, fixed, permeabilized, and labeled
with fluorescent antibodies and examined by microscopy (Fig.
4B). When RR1 and RR2 are both expressed without BPLF1
1-246, RR1 and RR2 are in the cytoplasm (Fig. 4B, top). When
RR1 and RR2 are expressed in the presence of BPLF1 1-246
(Fig. 4B, middle), localization of RR1 and RR2 remains
FIG. 3. EBV RR2 interacts with BPLF1 1-246. 293T cells were
transfected with BPLF1 1-246, EBV RR2, or both as indicated. IPs
were done using FLAG antibody followed by Western blotting (WB)
with myc antibodies. myc-tagged RR2 is highlighted with an arrow.
Input controls (20% of total cell lysate) are located at the bottom.
FIG. 4. EBV RR1, RR2, and BPLF1 1-246 localize in the cytoplasm of 293T cells. (A) 293T cells were transfected with EBV RR1, RR2, and
BPLF1 1-246 for 48 h. Fractionated extracts were analyzed by Western blotting (WB). The notation above the blots indicates the transfecting
plasmids. The notation to the right indicates the protein blotted against. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) served as a
cytoplasmic marker, and histone H1 served as the nuclear marker. (B) 293T cells were transfected with HA-tagged RR1, c-myc-tagged RR2, and
FLAG-tagged BPLF1 1-246 as indicated to the left. Immunofluorescence staining was performed with antibody against HA, myc, and FLAG.
Nuclear DAPI staining is shown in blue. All panels represent 100 magnification. Top panels depict cells transfected with RR1 and RR2 stained
for RR1 and RR2. Middle and bottom panels depict cells transfected with RR1, RR2, and BPLF1 1-246 stained for RR1 and RR2 or RR1 and
BPLF1 1-246, respectively. Merged images are shown to the right.
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largely cytoplasmic but seems to be in a more ordered struc-
ture. It should also be noted that a small amount of RR2 may
now be associated with the nucleus, which was not observed
when analyzed by cell fractionation (Fig. 4A). BPLF1 1-246 is
located in both the cytoplasm and nucleus of the cell when
RR1, RR2, and BPLF1 1-246 are coexpressed (Fig. 4B, bot-
tom). BPLF1 1-246 colocalizes with R1 and R2 in the cyto-
plasm of 293T cells as shown in the merged pictures (Fig. 4B).
EBV RR is ubiquitinated on its large subunit and is deu-
biquitinated by BPLF1 1-246. Since BPLF1 1-246 interacted
with the EBV RR, we next investigated whether it was a target
for the DUB activity. The first step was to determine if EBV
RR is ubiquitinated. No reports of ubiquitination of EBV RR
were found; however, ubiquitination of the small subunit
(RR2) of mammalian RR has been reported (8). To investi-
gate the ubiquitination of RR, we made use of an in vitro
ubiquitination system. Briefly, 293EBV cells (11) were trans-
fected with EBV subunits RR1, RR2, or both. After 48 h, the
transfected cells were harvested and lysed and samples were
placed in reaction buffer containing fraction II rabbit reticulo-
cytes to provide E1 and E2 enzymes and His-tagged Ub, Mg-
ATP, and Ub-al to inhibit cellular DUBs in reticulocytes. After
a 1-h incubation at 37°C, Western blotting displayed a banding
pattern consistent with the ubiquitination of RR1 (Fig. 5A).
RR2 ubiquitination was not observed regardless of whether
RR1 was present. The arrows in Fig. 5A indicate the RR1,
RR2, and ubiquitinated forms. RR1 was almost entirely mo-
noubiquitinated; however, fainter bands could be observed,
which may relate to polyubiquitinated products. A small
amount of ubiquitinated RR1 could also be observed at 0 h,
which may have occurred intracellularly from endogenous
sources. Faster-migrating bands below RR1 were identified but
are believed to be nonspecific. These data demonstrate that
ubiquitination occurs only when both subunits of EBV RR are
expressed together and that only RR1 is ubiquitinated in vitro.
We believe these are the first reports of EBV RR ubiquitina-
tion and that they offer a contrast with cellular RR in which
only RR2 is ubiquitinated.
We next tested whether DUB activity of BPLF1 1-246 could
remove Ub from RR1 in vitro in a modified deubiquitination
system. 293EBV cells were transfected with the large and
small subunits of EBV RR, harvested, split into four equal
fractions, and placed in reaction buffer as outlined above ex-
cept that Ub-al was omitted. His-tagged Ub was added where
noted (Fig. 5B). Samples were then placed at 37°C for 1 h, 5
M of purified BPLF1 1-246 was added where noted, and
incubation continued for another hour. The immunoblot was
overexposed to detect ubiquitinated RR1. The small amount
of ubiquitinated product detected is most likely due to cellular
DUBs present in the rabbit reticulocytes. A band migrating
above RR1 was detected in lane 3 (Fig. 5B), consistent with
ubiquitination as all reaction mixtures were the product of one
transfected sample. In lane 4 (Fig. 5B), ubiquitinated RR1 was
not detected, indicating that BPLF1 1-246 is capable of remov-
ing Ub from RR1. While the additional band migrating above
RR1 is approximately 8 kDa larger (the molecular mass of Ub)
than RR1, it is not possible to determine if ubiquitination/
deubiquitination is the result of monoubiquitin or polyubiq-
uitin chain addition/removal, as additional ubiquitinated prod-
ucts may be too faint to be detected in this experiment.
We next determined if RR1 could be ubiquitinated and
subsequently deubiquitinated by BPLF1 1-246 in vivo. 293T
cells were transfected with RR1, RR2, BPLF1 1-246, and Ub
as indicated (Fig. 5C). After 30 h, cells were harvested and
proteins were separated by SDS-PAGE, transferred to nitro-
cellulose, and probed with antibody against EBV RR1 (anti-
EaR). Overexpression of Ub resulted in ubiquitinated RR1 but
only when both RR1 and RR2 were expressed together (Fig.
5C, lane 2 versus lane 3). This is in agreement with the obser-
vation that RR1 ubiquitination occurs only when both subunits
are expressed (Fig. 5A). RR2 is likely necessary for proper
folding of RR1 and its subsequent ubiquitination. The addition
of overexpressed BPLF1 1-246 results in the loss of the ubiq-
uitinated RR1 forms (Fig. 5C, lanes 3 and 4). Repeated ex-
FIG. 5. EBV RR1 is ubiquitinated in vitro and in vivo and is
deubiquitinated by BPLF1 1-246. (A) 293EBV cells were transfected
with RR1, RR2, or both as indicated. Cells were harvested after 48 h,
and lysates were mixed with reaction buffer containing rabbit reticu-
locytes and exogenous Ub. Samples were then incubated at 37°C for
the indicated amounts of time and subjected to Western blotting
(WB). The top panel shows probing with HA antibody, and the bottom
panel shows probing with c-myc antibody. The locations of RR1, RR2,
and ubiquitinated RR1 (Ub-RR1) bands are indicated by arrows.
(B) 293EBV cells were transfected with EBV RR1 and RR2. Cells
were harvested after 48 h, lysates were mixed with reaction buffer, and
exogenous Ub was added where indicated, followed by incubation of
samples at 37°C for 1 h. Purified BPLF1 1-246 was added to the
indicated samples, and the reaction was continued for another hour at
37°C. Arrows note the location of RR1 and ubiquitinated RR1. The
blot was probed with anti-EBV EaR (RR1) and is overexposed to show
RR1 ubiquitination. (C) 293T cells were transfected with RR1, RR2,
and BPLF1 1-246 as indicated. All samples were additionally trans-
fected with HA-tagged Ub and subjected to Western blotting against
RR1. Arrows note the location of RR1 and ubiquitinated RR1.
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periments resulted in the same banding pattern. These results
suggest that EBV RR1 is ubiquitinated and that BPLF1 1-246
can deubiquitinate RR1 in vivo as well as in vitro. The more
slowly migrating bands suggest additional ubiquitinated forms
that may also be reduced in amount. We were unable to show
by IP the presence of ubiquitinated RR1, perhaps due to the
small amount of ubiquitinated RR1 or the inability of the
antibody we used to recognize the modified RR1.
BPLF1 1-246 decreases RR activity. Preliminary tests of
EBV RR activity in vitro resulted in enzymatic activity that was
too low and variable to permit conclusive study of the effect of
BPLF1 on the viral RR. Therefore, we moved to an in vivo
system to measure EBV RR activity. After verifying that EBV
RR could be deubiquitinated, we examined whether the enzy-
matic activity of BPLF1 influenced the RR activity. RR activity
was assayed by adding [3H]cytidine to the medium of 293T
cells transfected with EBV RR1 and RR2 alone or together
with BPLF1 1-246 or BPLF1 C61S. Cytidine is converted to
CDP after entering the cell and then to dCDP by cellular or
EBV RR activity, and it has been shown that there is a good
correlation between RR activity and incorporation of labeled
cytidine into DNA (41). Cells transfected with EBV RR1 and
RR2 produced an increase in incorporated 3H-labeled DNA
above background levels produced by cellular RR (Fig. 6).
Introduction of BPLF1 1-246 into the system significantly de-
creased RR activity, whereas the inactive BPLF1 C61S mutant
did not result in a similar decrease in RR activity. These results
indicate that EBV RR increases total RR activity above en-
dogenous cellular levels and that the deubiquitinating activity
of BPLF1 affects RR function by suppressing its activity
through removal of Ub.
DISCUSSION
Ubiquitination and deubiquitination are important pro-
cesses in both viral and cellular life cycles. However, until the
surprising discovery that viruses encode deubiquitinating en-
zymes, only cellular DUBs were known to carry out deubiq-
uitination of ubiquitinated proteins (34). In the case of EBV,
cellular DUBs have been implicated in deubiquitination and
stabilization of -catenin in latently infected cells (36). In con-
trast, the newly discovered class of herpesviral DUBs is ex-
pressed during the viral lytic cycle (35). These DUBs display
very little homology to known cellular DUBs, although the
active site is identical to those of many cellular DUBs (25). The
function of viral DUBs, whether directed at viral replicative
processes or at cellular targets needed for viral replication,
remains completely unknown. After determining that the full-
length gene product of BPLF1 is important for viral replica-
tion, we undertook these experiments in order to explore pos-
sible functions of the EBV DUB by identifying substrates for
the enzyme. We focused on the EBV RR as a likely target.
We first found that the N-terminal 246 amino acids of
BPLF1 can function alone as a DUB and that one of the
strictly conserved active-site residues (C61S) is essential for its
function. In addition, the deubiquitinating activity of BPLF1
1-246 cleaves both K48- and K63-linked Ub chains. This result
suggests that EBV DUB activity may be involved in processes
that protect the substrate from proteasomal degradation,
which is typically associated with K48-linked Ub chains, and
that it may also play a functional or regulatory role, exempli-
fied by K63-linked Ub protein chains. Interestingly, this result
differs from that reported with the HSV homolog, UL36, which
appears to be specific for K48-linked ubiquitination. This re-
sult suggests that activity of EBV DUB may be broader than
that reported for HSV (25). Future studies with full-length
BPLF1 protein may uncover specificity for protein targets or
the type of Ub cleavage that cannot be detected with the
N-terminal fragment. It is also still unknown if viral DUBs can
cleave Ub precursors, which would expand further the role of
the newly discovered viral enzymes.
Members of the Herpesviridae encode their own RRs. How-
ever, HSV RR differs from EBV RR in both protein size and
function. Both contain RR activity, but HSV-encoded RR also
contains kinase and antiapoptotic activity (27, 31, 37, 38).
However, the regions that encode these activities are not rep-
resented in the EBV RR gene. The only verified function of
EBV RR is its RR activity. This work adds significantly to the
little that is known about EBV RR function and its regulation
and should open a new area for the study of viral and possibly
cellular RRs.
The localization of BPLF1 1-246 was not changed by the
presence of EBV RR1 or RR2 or both. These findings seem
logical since the full-length BPLF1 herpesviral homolog
(UL36) plays a role in viral maturation in that it is important
for release of the viral genome to the nucleus (2), and there is
accumulation of nonenveloped particles in the cytoplasm when
functional UL36 is absent (12). Additionally, it was found that
EBV RR1 and RR2 colocalize in the cytoplasm, consistent
with published literature for cellular RR in which both RR1
and RR2 are found in the cytoplasm (15, 16). EBV RR1 seems
to undergo a locational shift when expressed in the presence of
RR2. These findings are compatible with operation of the
subunits in a complex and suggest that both subunits may be
required for proper folding and function of the enzyme.
We show that EBV RR1 but not RR2 is ubiquitinated both
in vitro and in vivo. This finding contrasts with the cellular
reductase in which RR2 is ubiquitinated, and enzymatic activ-
FIG. 6. BPLF1 1-246 decreases RR activity. 293T cells were trans-
fected with labeled plasmids as indicated. After 24 h, [3H]cytidine was
added to the medium for an additional 24 h. Cells were harvested and
treated with RNase, and DNA was extracted and purified. 3H incor-
poration into DNA was determined by scintillation counting. Experi-
ments were performed in triplicate; error bars represent the standard
error of the mean.
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ity is determined by the stability of RR2 (4, 14). Whether this
difference between cellular and viral RRs also applies to other
herpesvirus RRs appears not to have been reported. However,
HSV RR is similar to cellular RR in that it is active only when
both subunits are expressed together. We also found that EBV
RR1 is ubiquitinated only when RR2 is present, which sup-
ports the idea that ubiquitination plays a regulatory role in RR
function since the enzyme is functional only when the subunits
can act as a complex. Additional experiments in which RR1
and RR2 were expressed in 293T cells in the presence of
various proteasome inhibitors and overexpressed Ub did not
result in an increase in RR1 protein levels (data not shown).
This finding suggests that ubiquitination of EBV RR1 affects
the function of the protein rather than targeting it for protea-
somal degradation.
Deubiquitination of RR1 in the presence of BPLF1 1-246
was demonstrated both in vivo and in vitro. These data indicate
not only that RR and BPLF1 1-246 interact but that EBV RR1
is also a substrate for deubiquitination by the viral enzyme.
Taken along with the findings that BPLF1 1-246 preferentially
cleaves K63-linked Ub chains and that no accumulation of
ubiquitinated RR1 is detected in the presence of proteasome
inhibitors, the data suggest that RR1 ubiquitination may up-
regulate RR activity and that deubiquitination of RR1 by
BPLF1 DUB activity may decrease RR activity.
Finally, RR activity was measured by following the conver-
sion of [3H]cytidine until its incorporation into DNA. Overex-
pression of EBV RR in 293T cells resulted in increased DNA
labeling, indicating that viral RR does increase the conversion
of nucleoside triphosphates to deoxynucleoside triphosphates
(dNTPs) compared with the negative control in which only
cellular enzymes are expressed. This is logical in the sense that
EBV is typically reactivated in resting B lymphocytes which are
depleted in their dNTP pools. During initial infection, EBV
RR may play a critical role in increasing dNTP levels to facil-
itate viral replication.
Decreases in RR activity were observed when BPLF1 1-246
was expressed but not with an enzymatically inactive mutant
DUB. Since herpesviral DUB activity is believed to be specific
for ubiquitinated substrates, it follows that BPLF1 downregu-
lates RR activity by the removal of Ub. The modest difference
observed in the loss of activity of RR may be due to the fact
that only a small percentage of RR was ubiquitinated in our
experiments. Future experiments are designed to determine if
EBV DUB activity is restricted to the viral RR or if it may also
influence cellular RR activity.
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